• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru.与抗结核药物不良反应相关的因素:秘鲁利马的一项病例对照研究。
PLoS One. 2011;6(11):e27610. doi: 10.1371/journal.pone.0027610. Epub 2011 Nov 16.
2
Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors.耐多药结核病病例的死亡率:与药物敏感结核病的比较及相关因素
PLoS One. 2015 Mar 19;10(3):e0119332. doi: 10.1371/journal.pone.0119332. eCollection 2015.
3
Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data.秘鲁利马结核患者的密切接触者和家庭成员的接触评估和异烟肼预防治疗:常规数据分析。
Trop Med Int Health. 2020 Mar;25(3):346-356. doi: 10.1111/tmi.13350. Epub 2019 Dec 12.
4
Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study.乌干达耐多药结核病患者死亡风险因素的病例对照研究。
BMC Infect Dis. 2021 Mar 22;21(1):292. doi: 10.1186/s12879-021-05967-2.
5
Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case-control study.埃塞俄比亚西北部耐多药结核病的危险因素:一项病例对照研究。
Transbound Emerg Dis. 2019 Jul;66(4):1611-1618. doi: 10.1111/tbed.13188. Epub 2019 Apr 15.
6
Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.儿童耐多药结核病的治疗和结局:系统评价和个体患者数据荟萃分析。
PLoS Med. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. eCollection 2018 Jul.
7
Impact of HIV infection on treatment outcome of tuberculosis in Europe.HIV感染对欧洲结核病治疗结果的影响。
AIDS. 2016 Apr 24;30(7):1089-98. doi: 10.1097/QAD.0000000000001016.
8
Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru.秘鲁利马市肺结核I类治疗早期治疗失败的识别
Int J Tuberc Lung Dis. 2004 Jan;8(1):52-8.
9
Self-reported risks for multiple-drug resistance among new tuberculosis cases: implications for drug susceptibility screening and treatment.新结核病例中多种药物耐药的自我报告风险:对药物敏感性筛查和治疗的影响。
PLoS One. 2011;6(10):e25861. doi: 10.1371/journal.pone.0025861. Epub 2011 Oct 14.
10
Management of extensively drug-resistant tuberculosis in Peru: cure is possible.秘鲁广泛耐药结核病的管理:治愈是有可能的。
PLoS One. 2008 Aug 13;3(8):e2957. doi: 10.1371/journal.pone.0002957.

引用本文的文献

1
Treatment of Drug-Resistant Tuberculosis with Bedaquiline, Pretomanid, Linezolid with or Without Moxifloxacin (BPaL/M): Feasibility and Implementation Challenges in Western Canada.使用贝达喹啉、普瑞玛尼、利奈唑胺联合或不联合莫西沙星(BPaL/M)治疗耐多药结核病:加拿大西部的可行性及实施挑战
J Assoc Med Microbiol Infect Dis Can. 2025 Apr 5;10(2):192-202. doi: 10.3138/jammi-2024-0034. eCollection 2025 Jun.
2
Genetic polymorphisms and adverse reactions to antituberculosis therapy.基因多态性与抗结核治疗的不良反应
Pharmacogenomics. 2025 Apr-Apr;26(5-6):207-221. doi: 10.1080/14622416.2025.2509479. Epub 2025 Jun 20.
3
Adverse drug reactions and contributing factors in patients with drug-resistant tuberculosis: A 7-year retrospective cohort study in Addis Ababa, Ethiopia.耐多药结核病患者的药物不良反应及相关因素:埃塞俄比亚亚的斯亚贝巴的一项7年回顾性队列研究
J Clin Tuberc Other Mycobact Dis. 2025 Mar 5;39:100515. doi: 10.1016/j.jctube.2025.100515. eCollection 2025 May.
4
Factors associated with mortality among laboratory-diagnosed drug-resistant tuberculosis patients on treatment, KwaZulu-Natal Province, 2017-2019.2017-2019 年,夸祖鲁-纳塔尔省实验室诊断耐多药结核病患者治疗期间死亡相关因素。
Pan Afr Med J. 2024 Apr 11;47:181. doi: 10.11604/pamj.2024.47.181.34571. eCollection 2024.
5
Impact of bedaquiline regimen on the treatment success rates of multidrug-resistant tuberculosis patients in Egypt.贝达喹啉方案对埃及耐多药结核病患者治疗成功率的影响。
Sci Rep. 2024 Jul 15;14(1):16247. doi: 10.1038/s41598-024-65063-8.
6
Evaluation of adverse reactions induced by anti-tuberculosis drugs among hospitalized patients in Wuhan, China: A retrospective study.中国武汉住院患者抗结核药物不良反应评估:一项回顾性研究。
Medicine (Baltimore). 2024 May 17;103(20):e38273. doi: 10.1097/MD.0000000000038273.
7
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.使用 IL-17 和 IL-23 抑制剂治疗潜伏性结核病的银屑病患者:一项回顾性、多国、多中心研究。
Am J Clin Dermatol. 2024 Mar;25(2):333-342. doi: 10.1007/s40257-024-00845-4. Epub 2024 Jan 24.
8
Clinical standards for the management of adverse effects during treatment for TB.肺结核治疗过程中不良反应管理的临床标准。
Int J Tuberc Lung Dis. 2023 Jul 1;27(7):506-519. doi: 10.5588/ijtld.23.0078.
9
Determinants of adverse reactions to first-line antitubercular medicines: a prospective cohort study.一线抗结核药物不良反应的决定因素:一项前瞻性队列研究。
J Pharm Policy Pract. 2023 Jun 8;16(1):70. doi: 10.1186/s40545-023-00577-6.
10
Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital, Uganda.耐多药结核病的药物不良反应及相关因素:乌干达姆巴拉拉地区转诊医院患者病历的回顾性研究
SAGE Open Med. 2023 May 3;11:20503121231171350. doi: 10.1177/20503121231171350. eCollection 2023.

本文引用的文献

1
Nutrition, diabetes and tuberculosis in the epidemiological transition.营养、糖尿病与结核在流行病学转变中的作用
PLoS One. 2011;6(6):e21161. doi: 10.1371/journal.pone.0021161. Epub 2011 Jun 21.
2
Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.印度泰米尔纳德邦耐多药结核病患者标准化治疗的结果。
Indian J Med Res. 2011 May;133(5):529-34.
3
Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs.抗结核药物:药物相互作用、不良反应及特殊情况下的应用。第 2 部分:二线药物。
J Bras Pneumol. 2010 Sep-Oct;36(5):641-56. doi: 10.1590/s1806-37132010000500017.
4
Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs.抗结核药物:药物相互作用、不良反应及特殊情况下的应用。第 1 部分:一线药物。
J Bras Pneumol. 2010 Sep-Oct;36(5):626-40. doi: 10.1590/s1806-37132010000500016.
5
Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.抗结核治疗致肝毒性的危险因素评估。
Indian J Med Res. 2010 Jul;132:81-6.
6
Adverse reactions to antituberculosis drugs in in-hospital patients: Severity and risk factors.住院患者抗结核药物的不良反应:严重程度及危险因素。
Rev Port Pneumol. 2010 May-Jun;16(3):431-51. doi: 10.1016/s0873-2159(15)30040-4.
7
Tuberculosis and nutrition.结核病与营养
Lung India. 2009 Jan;26(1):9-16. doi: 10.4103/0970-2113.45198.
8
Treatment of latent tuberculosis infection in HIV infected persons.HIV感染者潜伏性结核感染的治疗。
Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD000171. doi: 10.1002/14651858.CD000171.pub3.
9
Hepatotoxicity of pyrazinamide: cohort and case-control analyses.吡嗪酰胺的肝毒性:队列研究与病例对照分析。
Am J Respir Crit Care Med. 2008 Jun 15;177(12):1391-6. doi: 10.1164/rccm.200802-355OC. Epub 2008 Apr 3.
10
Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.抗结核药物所致肝毒性:简明最新综述
J Gastroenterol Hepatol. 2008 Feb;23(2):192-202. doi: 10.1111/j.1440-1746.2007.05207.x. Epub 2007 Nov 6.

与抗结核药物不良反应相关的因素:秘鲁利马的一项病例对照研究。

Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru.

机构信息

School of Medicine, Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas, Lima, Peru.

出版信息

PLoS One. 2011;6(11):e27610. doi: 10.1371/journal.pone.0027610. Epub 2011 Nov 16.

DOI:10.1371/journal.pone.0027610
PMID:22110689
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3217998/
Abstract

BACKGROUND

Long-term exposure to anti-tuberculosis medication increases risk of adverse drug reactions and toxicity. The objective of this investigation was to determine factors associated with anti-tuberculosis adverse drug reactions in Lima, Peru, with special emphasis on MDR-TB medication, HIV infection, diabetes, age and tobacco use.

METHODOLOGY AND RESULTS

A case-control study was performed using information from Peruvian TB Programme. A case was defined as having reported an anti-TB adverse drug reaction during 2005-2010 with appropriate notification on clinical records. Controls were defined as not having reported a side effect, receiving anti-TB therapy during the same time that the case had appeared. Crude, and age- and sex-adjusted models were calculated using odds ratios (OR) and 95% confidence intervals (95%CI). A multivariable model was created to look for independent factors associated with side effect from anti-TB therapy. A total of 720 patients (144 cases and 576 controls) were analyzed. In our multivariable model, age, especially those over 40 years (OR = 3.93; 95%CI: 1.65-9.35), overweight/obesity (OR = 2.13; 95%CI: 1.17-3.89), anemia (OR = 2.10; IC95%: 1.13-3.92), MDR-TB medication (OR = 11.1; 95%CI: 6.29-19.6), and smoking (OR = 2.00; 95%CI: 1.03-3.87) were independently associated with adverse drug reactions.

CONCLUSIONS

Old age, anemia, MDR-TB medication, overweight/obesity status, and smoking history are independent risk factors associated with anti-tuberculosis adverse drug reactions. Patients with these risk factors should be monitored during the anti-TB therapy. A comprehensive clinical history and additional medical exams, including hematocrit and HIV-ELISA, might be useful to identify these patients.

摘要

背景

长期暴露于抗结核药物会增加不良反应和毒性的风险。本研究旨在确定秘鲁利马与抗结核药物不良反应相关的因素,特别强调耐多药结核(MDR-TB)药物、HIV 感染、糖尿病、年龄和吸烟。

方法和结果

采用秘鲁结核病规划的信息进行病例对照研究。病例定义为在 2005-2010 年期间报告有抗结核药物不良反应,并在临床记录中进行了适当通知。对照定义为在病例出现期间没有报告副作用,接受了抗结核治疗。使用比值比(OR)和 95%置信区间(95%CI)计算了粗比值比和年龄及性别调整模型。建立多变量模型以寻找与抗结核治疗副作用相关的独立因素。共分析了 720 名患者(144 例病例和 576 例对照)。在多变量模型中,年龄,特别是 40 岁以上(OR=3.93;95%CI:1.65-9.35)、超重/肥胖(OR=2.13;95%CI:1.17-3.89)、贫血(OR=2.10;95%CI:1.13-3.92)、MDR-TB 药物(OR=11.1;95%CI:6.29-19.6)和吸烟(OR=2.00;95%CI:1.03-3.87)与不良反应独立相关。

结论

老年、贫血、MDR-TB 药物、超重/肥胖状态和吸烟史是与抗结核药物不良反应相关的独立危险因素。这些危险因素的患者应在抗结核治疗期间进行监测。全面的临床病史和额外的医学检查,包括血细胞比容和 HIV-ELISA,可能有助于识别这些患者。